Foslewodopa/foskarbidopa - zastępca “złotego standardu” w leczeniu choroby Parkinsona

Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 2021;20(5):385-397. doi:10.1016/S1474-4422(21)00030-2

Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020;27(1):27-42. doi:10.1111/ene.14108

Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med. 2020;36(1):1-12. doi:10.1016/j.cger.2019.08.002

Cabreira V, Massano J. Doença de Parkinson: Revisão Clínica e Atualização [Parkinson's Disease: Clinical Review and Update]. Acta Med Port. 2019;32(10):661-670. doi:10.20344/amp.11978

Aldred J, Freire-Alvarez E, Amelin AV, et al. Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study [published correction appears in Neurol Ther. 2023 Dec;12(6):1959-1960. doi: 10.1007/s40120-023-00554-w.]. Neurol Ther. 2023;12(6):1937-1958. doi:10.1007/s40120-023-00533-1

Rosebraugh M, Liu W, Neenan M, Facheris MF. Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion. J Parkinsons Dis. 2021;11(4):1695-1702. doi:10.3233/JPD-212813

Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med. 2020;36(1):1-12. doi:10.1016/j.cger.2019.08.002

Surmeier D.J., Obeso J.A., Halliday G.M.: Selective neuronal vulnerability in Parkinson disease, Nature Reviews Neuroscience., 2017, 18, 101-113.

Recasens A., Dehay B., Bové J., Carballo-Carbajal I., Dovero S., Pérez-Villalba A., Fernagut P.O., Blesa J., Parent A., Perier C., Fariñas I., Obeso J.A., Bezard E., Vila M.: Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys, Annals of Neurolgy, 2014, 75, 351-362

Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017;124(8):901-905. doi:10.1007/s00702-017-1686-y

Reich SG, Savitt JM. Parkinson's Disease. Med Clin North Am. 2019;103(2):337-350. doi:10.1016/j.mcna.2018.10.014

Day JO, Mullin S. The Genetics of Parkinson's Disease and Implications for Clinical Practice. Genes (Basel). 2021;12(7):1006. Published 2021 Jun 30. doi:10.3390/genes12071006

Poewe W. Non-motor symptoms in Parkinson’s disease. European Journal of Neurology. 2008;15(s1):14-20. doi:https://doi.org/10.1111/j.1468-1331.2008.02056.x

Meijer F JA, Goraj B, Bloem B R, Esselink R AJ. Clinical Application of Brain MRI in the Diagnostic Work-up of Parkinsonism. J Parkinsons Dis. 2017;7(02):211–217. doi: 10.3233/JPD-150733. [DOI] [PMC free article] [PubMed] [Google Scholar]

Saunders-Pullman R, Raymond D, Ortega R A et al. International Genetic Testing and Counseling Practices for Parkinson's Disease. Mov Disord. 2023;38(08):1527–1535. doi: 10.1002/mds.29442. [DOI] [PMC free article] [PubMed] [Google Scholar]

Jankovic J. Parkinson"s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368–76.doi:10.1136/jnnp.2007.131045 pmid:http://www.ncbi.nlm.nih.gov/pubmed/18344392 Abstract/FREE Full TextGoogle Scholar

Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain : a journal of neurology. 1991;114(Pt 5):2283–301.

Greenland JC, Barker RA. The Differential Diagnosis of Parkinson’s Disease. In: Stoker TB, Greenland JC, editors. Parkinson’s Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane (AU): Codon Publications; 2018 Dec 21. Table 1, The clinical diagnostic criteria for Parkinson’s disease, based on the Movement Disorder Society guidelines. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536715/table/Ch6-t0001/ doi: 10.15586/codonpublications.parkinsonsdisease.2018.ch6

Jankovic J, Tan EKParkinson’s disease: etiopathogenesis and treatmentJournal of Neurology, Neurosurgery & Psychiatry 2020;91:795-808.

Fahn S. The history of dopamine and levodopa in the treatment of Parkinson’s disease. Mov Disord 2008; 23 (supl. 3): S494- S508.

Trenkwalder C , Kuoppamäki M , Vahteristo M , et al Increased dose of carbidopa with levodopa and entacapone improves “off” time in a randomized trial. Neurology 2019;92:e1487–96.doi:10.1212/WNL.0000000000007173 PubMedGoogle Scholar

Salat D, Tolosa E. Levodopa in the treatment of Parkinson's disease: current status and new developments. J Parkinsons Dis. 2013;3(3):255-269. doi:10.3233/JPD-130186

Rizek P, Kumar N, Jog MS. An update on the diagnosis and treatment of Parkinson disease. CMAJ. 2016 Nov 01;188(16):1157-1165. [PMC free article] [PubMed] [Reference list]

Gandhi KR, Saadabadi A. Levodopa (L-Dopa). National Library of Medicine. Published April 17, 2023. https://www.ncbi.nlm.nih.gov/books/NBK482140/

Chaudhuri KR, Kovács N, Pontieri FE, et al. Levodopa Carbidopa Intestinal Gel in Advanced Parkinson's Disease: DUOGLOBE Final 3-Year Results. J Parkinsons Dis. 2023;13(5):769-783. doi:10.3233/JPD-225105

Niemann N , Jankovic J Juvenile parkinsonism: differential diagnosis, genetics, and treatment. Parkinsonism Relat Disord 2019;67:74–89.doi:10.1016/j.parkreldis.2019.06.025 CrossRefPubMedGoogle Scholar

Newman EJ, Grosset DG, Kennedy PG. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care. 2009;10(1):136-40. [PubMed] [Reference list]

Sofia A, Pinto M, José M, Carolina M. Parkinson’s Disease and development of levodopa induced motor complications: Influence of baseline features and first medical approach. Porto Biomedical Journal. 2016;1(4):136-141. doi:https://doi.org/10.1016/j.pbj.2016.08.001

Jarosław Sławek, Bogucki A, Dariusz Koziorowski, Rudzińska M. Agoniści dopaminy w leczeniu choroby Parkinsona i zespołu niespokojnych nóg — rekomendacje ekspertów Polskiego Towarzystwa Choroby Parkinsona i Innych Zaburzeń Ruchowych oraz Sekcji Schorzeń Pozapiramidowych Polskiego Towarzystwa Neurologicznego. Polski Przegląd Neurologiczny. 2016;12(1):1-14. Accessed April 15, 2025. https://journals.viamedica.pl/polski_przeglad_neurologiczny/article/view/47208/36505

Lees A., Turner K. Apomorphine for Parkinson’s disease. Pract Neurol 2002; 2: 280-286.

Menon R., Stacy M. Apomorphine in the treatment of Parkinson’s disease. Expert Opin Pharmacother 2007; 8: 1941-1950.

Harder S., Baas H., Demisch L., et al. Dose response and concentration response relationship of apomorphine in patients with Parkinson’s disease and end-of-dose akinesia. Int J Clin Pharmacol Ther 1998; 36: 355-362.

Hofstee D.J., Neef C., van Laar T., et al. Pharmacokinetics of apomorphine in Parkinson’s disease: plasma and cerebrospinal fluid levels in relation to motor responses. Clin Neuropharmacol 1994; 17: 45-52

Verhagen M.L., Locatelli E.R., Bravi D., et al. Apomorphine responses in Parkinson’s disease and pathogenesis of motor complications. Neurology 1997; 48: 369-372.

Colzi A., Turner K., Lees A.J. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1998; 64: 573-576.

Głęboka stymulacja mózgu w chorobie Parkinsona - kliniczne i techniczne aspekty leczenia. www.mp.pl. https://www.mp.pl/pacjent/neurologia/choroby/159336

Krishnan S, Pisharady KK, Divya KP, Shetty K, Kishore A. Deep brain stimulation for movement disorders. Neurol India. 2018;66(Supplement):S90-S101. doi:10.4103/0028-3886.226438

Dostrovsky JO, Levy R, Wu JP, Hutchison WD, Tasker RR, Lozano AM. Microstimulation-induced inhibition of neuronal firing in human globus pallidus. J Neurophysiol. 2000;84(1):570-574. doi:10.1152/jn.2000.84.1.570

Malek N. Deep Brain Stimulation in Parkinson’s Disease. Neurology India. 2019;67(4):968. doi:https://doi.org/10.4103/0028-3886.266268

Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2011;68(2):165. doi:10.1001/archneurol.2010.260

Olson M, Shill HA, Ponce FA, Aslam S. Deep brain stimulation in PD: risk of complications, morbidity, and hospitalizations: a systematic review. Frontiers in Aging Neuroscience. 2023;15. doi:https://doi.org/10.3389/fnagi.2023.1258190

Soileau MJ, Aldred J, Budur K, et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial [published correction appears in Lancet Neurol. 2023 Mar;22(3):e5. doi: 10.1016/S1474-4422(23)00048-0.]. Lancet Neurol. 2022;21(12):1099-1109. doi:10.1016/S1474-4422(22)00400-8

Savaryn JP, Smith RL, Rosebraugh M, et al. Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC-HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel. Pharmacol Res Perspect. 2024;12(2):e1190. doi:10.1002/prp2.1190

Rosebraugh M, Neenan M, Facheris M. Comparability of Foslevodopa/Foscarbidopa Pharmacokinetics in Healthy Asian and White Participants. Clinical Pharmacology in Drug Development. Published online November 16, 2022. doi:https://doi.org/10.1002/cpdd.1201

Chaudhuri KR, Facheris MF, Bergmans B, et al. Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa. Mov Disord Clin Pract. 2024;11(7):861-866. doi:10.1002/mdc3.14018

Sakuramoto H, Fujita H, Ogaki K, Suzuki K. A patient with Parkinson's disease whose sleep status improved after the introduction of continuous subcutaneous foslevodopa/foscarbidopa infusion. Clin Park Relat Disord. 2024;11:100292. Published 2024 Dec 2. doi:10.1016/j.prdoa.2024.100292

Mendes-Bastos P, Simoes RM. Algorithm for managing infusion site adverse events caused by subcutaneous foslevodopa/foscarbidopa and other device-aided therapies for advanced Parkinson's disease. Parkinsonism Relat Disord. Published online October 28, 2024. doi:10.1016/j.parkreldis.2024.107185

Yoshihara N, Nishikawa N, Watanabe R, Hattori N. Skin Inflammatory Reactions in Patients with Continuous Subcutaneous Injection of Foslevodopa-Foscarbidopa Hydrate: Histopathology. Mov Disord. 2025;40(2):378-379. doi:10.1002/mds.30069

Telarović S, Čondić Jurjević L. Subcutaneous administration of foslevodopa/foscarbidopa (PRODUODOPA®) in arm and thigh due to giant epigastric hernia: a case report. Neurol Sci. Published online December 18, 2024. doi:10.1007/s10072-024-07928-4

Fung VSC, Aldred J, Arroyo MP, et al. Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance. Clin Park Relat Disord. 2024;10:100239. Published 2024 Feb 10. doi:10.1016/j.prdoa.2024.100239